by Frank Bergman, Slay News:
A group of Japan’s leading oncology scientists has raised the alarm after uncovering evidence that Covid mRNA “vaccines” dramatically reduce the survival rate of cancer patients.
The findings were revealed by a research team led by Dr. Makoto Abue of the Miyagi Cancer Center in Natori, Japan.
Makoto’s team was made up of some of Japan’s most highly respected experts from the Miyagi Cancer Center Research Institute, including:
TRUTH LIVES on at https://sgtreport.tv/
- Mai Mochizuki, Divisions of Cancer Stem Cell
- Rie Shibuya-Takahashi, Divisions of Cancer Stem Cell
- Kensuke Ota, Department of Gastroenterology
- Yuta Wakui, Department of Gastroenterology
- Wataru Iwai, Department of Gastroenterology
- Jun Kusaka, Department of Gastroenterology
- Masashi Saito, Department of Gastroenterology
- Shinichi Suzuki, Department of Gastroenterology
- Ikuro Sato, Department of Pathology
- Keiichi Tamai, Divisions of Cancer Stem Cell
The team conducted a major study to investigate surges in rapidly spreading and highly aggressive cancers among people who received Covid mRNA vaccines.
Some of America’s top oncologists have dubbed this phenomenon “turbo cancer.”
The study found that the prognosis in cancer patients worsened after each dose of the “vaccine.”
Notably, they found dramatically worsened prognoses in patients with pancreatic cancer (PC).
The results of the study were published in the journal PrePrints.
The study assessed clinical outcomes and immune markers in 272 patients diagnosed between 2018 and 2023.
The investigators report that patients who received three or more doses of mRNA vaccines exhibited significantly shorter overall survival.
Disturbingly, the researchers found that the average survival period halved among those who received Covid “vaccines.”
The average survival period following a pancreatic cancer diagnosis plummeted to 10.3 months among vaccinated patients compared to 20.8 months for unvaccinated.
The finding confirms that “vaccinated” patients’ survival time was reduced by over 50%.
